Asthma drug, Cinqair, receives FDA approval
by Press Release from Outbreak News Today on (#181S6)
The U.S. Food and Drug Administration today approved Cinqair (reslizumab) for use with other asthma medicines for the maintenance treatment of severe asthma in patients aged 18 years and older. Cinqair is approved for patients who have a history of severe asthma attacks (exacerbations) despite receiving their current asthma medicines. Asthma is a chronic disease ["]
